The S&P 500 is only about 3% from its recent record high despite a tariff panic sell-off, negative investor sentiment and stock outflows.Trading Nationread more
A sell-off in chip stocks intensified on Monday following a report that semiconductor makers are cutting ties with Huawei following the Trump administration's restrictions.Marketsread more
Ford Motor said Monday that it is laying off about 7,000 salaried workers, about 10% of that global workforce, as part of a restructuring plan designed to save the No. 2...Autosread more
President Trump stands a chance of creating a new economic world order in his China trade fight, says the chief economic advisor of Allianz.Economyread more
Most U.S. hedge funds aren't expecting another big stock market sell-off as more firms curb bets on volatility, according to Nomura.Marketsread more
People investing in some technology stocks should not expect them to go up anytime soon, warns the "Mad Money" host.Investingread more
Google has suspended business activity involving the transfer of hardware, software and key technical services with Huawei. Analysts say that could be a big blow to the...Technologyread more
Sprint and T-Mobile US on Monday will announce a series of changes to their $26 billion deal, while U.S. regulators are expected to announce agreement on the conditions...Technologyread more
Wedbush cuts its price target on Tesla shares to $230 from $275.Investingread more
The suit claims Lyft failed to disclose issues it knew about concerning its bike-sharing program and labor.Technologyread more
Robert Smith announced that he and his family would set up a grant to pay off the nearly 400 graduating seniors' student loans. The total gift is estimated at $40 million.Personal Financeread more
Bristol-Myers Squibb shareholders approved the pharmaceutical giant's $74 billion acquisition of cancer drugmaker Celgene in a vote on Friday.
The deal, announced in January, was a hard sell to Bristol shareholders from the start, and the approval concludes a tumultuous period for Bristol, which saw pushback from institutional investors.
The acquisition adds about $32 billion in fresh debt to Bristol's balance sheet while assuming $20 billion in Celgene's debt, the companies said at the time.
More than 70% of eligible shareholders voted for the deal, the company said Friday. Roughly 24% of shareholders voted against the deal, and 1% abstained. Both Bristol and Celgene shares were slightly higher in morning trading.
"We are pleased with the outcome of today's Special Meeting and thank our shareholders for their support for this combination," Bristol's Chairman and CEO Giovanni Caforio said in a statement.
Buying Celgene was seen by Wall Street analysts as giving Bristol more cancer drugs at a time when its immuno-oncology portfolio struggles to keep up with rival Merck's. Bristol's blockbuster Opdivo, which boosts the immune system to attack cancer, has fallen behind its leading competitor, Merck's Keytruda.
Hedge funds Wellington Management and Starboard Value in late February said the deal didn't sit well with them. Wellington — which is Bristol's largest institutional holder — said the deal asked Bristol shareholders to accept too much risk. Starboard cited similar concerns, saying the Celgene deal was "poorly conceived and ill-advised."
Starboard eventually ended its fight against the buyout once Institutional Shareholder Services and Glass Lewis recommended Bristol-Myers shareholders vote in favor of its bid.
For more on investing in health-care innovation, click here to join CNBC at our Healthy Returns Summit in New York City on May 21.
Bristol said Friday the deal, which is expected to close in the third quarter of this year, will create a "premier innovative biopharma company with leading scientific capabilities."
"We look forward to bringing the companies together, which we believe will deliver significant shareholder value," Caforio said.